HC Wainwright & Co. Maintains Buy on Context Therapeutics, Raises Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on Context Therapeutics (NASDAQ:CNTX) and raises the price target from $4 to $5.
May 09, 2024 | 7:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Context Therapeutics and increases the price target from $4 to $5.
The upgrade in the price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the stock, suggesting an expectation of upward movement in the stock's price in the short term. This is based on the analyst's research, market trends, and the company's performance or potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100